Imatinib is approved for first-line treatment in CML [72], but patients become resistant to this treatment due to point mutations in the Abl gene resulting in substitutions of amino acid residues in the Abl protein sequence. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.